Welcome to our dedicated page for NORD ANGLIA ED news (Ticker: NORD), a resource for investors and traders seeking the latest updates and insights on NORD ANGLIA ED stock.
Nordicus Partners Corporation (OTCQB: NORD) issues frequent updates about its activities as a business accelerator, holding company, and financial consulting company focused on Nordic and U.S. life sciences. Its news flow centers on the progress of its preclinical biotech subsidiaries, corporate developments, and capital markets actions.
Readers of the NORD news page can follow detailed announcements from Orocidin A/S, Bio-Convert A/S, and NoviThera ApS, all of which are owned or majority owned by Nordicus. Recent releases describe Orocidin’s preclinical efficacy and toxicity studies for its periodontitis candidate QR-01, including animal model results and the development of a cGMP-compliant manufacturing process in collaboration with Syngene International Limited. Bio-Convert’s updates cover regulatory feedback from the Danish Medicines Agency for QR-02 in oral leukoplakia and its proprietary mucoadhesive oral formulation. NoviThera’s news focuses on preclinical psoriasis research and animal efficacy studies involving a monoclonal antibody approach.
In addition to scientific and development milestones, Nordicus publishes corporate and financing news. Examples include private placements of restricted common stock reported in Form 8-K filings, an application to uplist its shares from the OTCQB Market to the Nasdaq Capital Market, and changes to its Board of Directors. These items provide insight into how Nordicus funds and governs its portfolio of life sciences assets.
Investors and observers can use the NORD news page to track the evolution of Nordicus’ pipeline in periodontitis, oral leukoplakia, and psoriasis, as well as its corporate finance and listing plans. Regularly reviewing this page offers a consolidated view of scientific, regulatory, and capital markets developments connected to Nordicus and its subsidiaries.
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.
The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.
Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.
QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.
Orocidin A/S, a subsidiary of Nordicus Partners (NORD), has introduced a breakthrough dental gel for long-term periodontitis treatment. The innovative low-viscosity gel features a unique active peptide and is designed for direct application into dental pockets by dentists using a syringe and flushing cannula.
The gel's key innovation lies in its formulation of triglycerides, monoglycerides, and water. Upon contact with oral cavity moisture, it forms a semi-solid bioadhesive crystalline matrix, enabling slow and localized release of the active ingredient. All components are biocompatible and FDA-approved for oral use.
Nordicus Partners (NORD) announced that its subsidiary, Orocidin A/S, will begin its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to be completed by Q3 2025, enabling the launch of the first pilot efficacy study in patients by year-end.
Orocidin is a proprietary treatment for periodontitis that addresses three key challenges: inflammation reduction, bacterial infection elimination, and bone/teeth regeneration. The company has filed patent applications to protect the product's innovative design.
The development represents a significant milestone in bringing this dental health solution to market, targeting an unmet medical need.
Nordicus Partners (OTCQB:NORD) has announced that its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert ApS, plan to initiate pilot efficacy studies in 2025. These studies will focus on patients with periodontitis and oral leukoplakia. The company clarified that both subsidiaries are currently in the preclinical phase, correcting information provided in previous press releases.
Nordicus Partners (OTCQB:NORD) announced that FINRA has removed the appending 'D' from its OTC equity symbol following the completion of a 20-day transition period related to its previously announced reverse split. The company's common stock will continue trading on the OTCQB market under the symbol 'NORD' starting December 9, 2024. The new CUSIP number following the reverse stock split is 28265K 304. Nordicus is a financial consulting company that specializes in helping Nordic and U.S. life sciences companies establish themselves in the U.S. market.
Nordicus Partners (OTCQB: NORD) has announced the acquisition of the remaining 5% shares in Orocidin A/S, a Denmark-based clinical-stage biopharmaceutical company focused on periodontitis treatment. The transaction involves 200,000 restricted common shares of Nordicus in exchange for the outstanding Orocidin shares, making Orocidin a 100% wholly-owned subsidiary of Nordicus. The deal strengthens Nordicus's position in facilitating Nordic and U.S. life sciences companies' establishment in the U.S. market.
Nordicus Partners (OTCQB: NORD) has announced an agreement to acquire Bio-Convert ApS, a Denmark-based clinical-stage biopharmaceutical company, in an all-stock transaction of 12 million restricted common shares. Bio-Convert specializes in developing treatments for oral leukoplakia, a potentially malignant disorder that can lead to oral cancer. The company is developing a proprietary mucoadhesive oral formulation that delivers medication without systemic absorption, aiming to eliminate lesions or reduce the malignant conversion rate to oral cancer. Bio-Convert plans to conduct a pilot efficacy study in patients with oral leukoplakia.
Nordicus Partners (OTCQB: NORD) announced a 1-for-10 reverse stock split of its common stock, effective November 8, 2024. The company's stock will continue trading on OTCQB under the symbol 'NORD' with a new CUSIP number 28265K 304. The reverse split was approved by stockholders and the Board of Directors on June 7, 2024. Transfer Online, Inc. will act as the transfer agent, and stockholders are not required to take any action as positions will be automatically adjusted.
Nordicus Partners (OTCQB: NORD) will host an investor relations webinar on July 10, 2024, at 9:00 AM Pacific time. The event will feature presentations by CEO Henrik Rouf and Chairman Peter Severin, who will elaborate on the company’s mission and investment strategy. Allan Wehnert, CEO of Nordicus’ 95% subsidiary Orocidin, will update attendees on Orocidin’s scientific progress. Additionally, details about Nordicus’ accelerator client, Bio-Convert, will be discussed. Interested participants can register for the webinar at the provided link.